San Diego-based Otonomy Inc., a company that makes treatments for the middle and inner ear, announced the appointment of Dr. Dean Hakanson as chief medical officer.

Hakanson has more than 16 years of industry experience in medical affairs, market access and health economic research with leading pharmaceutical companies including Novartis, Bristol-Myers Squibb, Genentech and GlaxoSmithKline.

Hakanson joins Otonomy from Novartis, where he served as the vice president and head of health economics and outcomes research for U.S. medical and drug regulatory affairs.

Prior to Novartis, he served as the vice president of health care access at Bristol-Myers Squibb and before that he served as the head of value-based healthcare/payer field team at Genentech. He also held positions of increasing responsibility at GlaxoSmithKline, most recently serving as vice president of medical affairs for commercial operations.